American Renal Associates (ARA) Stock Price, News & Analysis

Company Overview

American Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of December 31, 2019, it operated 246 dialysis clinics in partnership with 400 nephrologist partners treating approximately 17,300 patients in 27 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts.

Key Stats

• Today's Range: $11.33 to $11.52
• 50-Day Range: $11.46 to $11.52
• 52-Week Range: $5.57 to $11.98
• Volume: 9,831 shs
• Average Volume: 106,940 shs
• Market Capitalization: $397.94 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ARA Stock Analysis - Frequently Asked Questions

How were American Renal Associates' earnings last quarter?

American Renal Associates Holdings, Inc. (NYSE:ARA) posted its quarterly earnings results on Wednesday, November, 11th. The company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.09. The firm earned $209.69 million during the quarter, compared to analysts' expectations of $211.50 million. American Renal Associates had a negative trailing twelve-month return on equity of 3.56% and a negative net margin of 2.04%.

When did American Renal Associates IPO?

American Renal Associates (ARA) raised $161 million in an IPO on Thursday, April 21st 2016. The company issued 7,500,000 shares at $20.00-$23.00 per share. BofA Merrill Lynch, Barclays and Goldman Sachs acted as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey and Leerink Partners were co-managers.

What other stocks do shareholders of American Renal Associates own?

Based on aggregate information from My MarketBeat watchlists, some other companies that American Renal Associates investors own include Zevra Therapeutics (KMPH), Madrigal Pharmaceuticals (MDGL), Exelixis (EXEL), Gilead Sciences (GILD), Spectrum Pharmaceuticals (SPPI), AbbVie (ABBV) and Bristol-Myers Squibb (BMY).

Company Calendar

• Last Earnings: 11/11/2020
• Today: 5/27/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Miscellaneous Health & Allied Services
• Sub-Industry: N/A
• Current Symbol: NYSE:ARA
• CIK: 1498068
• Web: www.americanrenal.com
• Phone: 978-922-3080
• Fax: N/A
• Employees: 4,977
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): $0.26
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-13,790,000.00
• Net Margins: -2.04%
• Pretax Margin: N/A
• Return on Equity: -3.56%
• Return on Assets: -0.24%

Debt

• Debt-to-Equity Ratio: 7.54
• Current Ratio: 1.05
• Quick Ratio: 1.02

Sales & Book Value

• Annual Sales: $822.52 million
• Price / Sales: 0.48
• Cash Flow: $1.69 per share
• Price / Cash Flow: 6.80
• Book Value: $2.59 per share
• Price / Book: 4.45

Miscellaneous

• Outstanding Shares: 34,543,000
• Free Float: N/A
• Market Cap: $397.94 million
• Optionable: Optionable
• Beta: 1.11